End-of-day quote
Taipei Exchange
23:00:00 26/06/2024 BST
|
5-day change
|
1st Jan Change
|
89.4
TWD
|
-0.11%
|
|
-0.11%
|
+9.02%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
24,991
|
21,212
|
17,813
|
17,843
|
20,746
|
24,407
|
-
|
Enterprise Value (EV)
1 |
23,717
|
21,176
|
17,798
|
18,305
|
21,217
|
23,583
|
22,620
|
P/E ratio
|
-43.1
x
|
-115
x
|
-37.8
x
|
-66.1
x
|
-106
x
|
93.4
x
|
23.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
35.5
x
|
29.4
x
|
43.1
x
|
31.7
x
|
42.2
x
|
17.1
x
|
12.5
x
|
EV / Revenue
|
33.7
x
|
29.3
x
|
43
x
|
32.5
x
|
43.1
x
|
16.6
x
|
11.6
x
|
EV / EBITDA
|
-79.7
x
|
3,016
x
|
-54
x
|
-517
x
|
-1,957
x
|
23.5
x
|
14.8
x
|
EV / FCF
|
-30.5
x
|
-83.3
x
|
-81.1
x
|
-
|
-673
x
|
-59.4
x
|
31.3
x
|
FCF Yield
|
-3.28%
|
-1.2%
|
-1.23%
|
-
|
-0.15%
|
-1.68%
|
3.2%
|
Price to Book
|
6.96
x
|
5.54
x
|
6.06
x
|
6.58
x
|
8.09
x
|
8.9
x
|
6.45
x
|
Nbr of stocks (in thousands)
|
252,183
|
252,220
|
252,311
|
252,374
|
252,999
|
273,010
|
-
|
Reference price
2 |
99.10
|
84.10
|
70.60
|
70.70
|
82.00
|
89.40
|
89.40
|
Announcement Date
|
26/03/20
|
26/03/21
|
31/03/22
|
10/03/23
|
20/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
704.5
|
722.5
|
413.4
|
563
|
491.8
|
1,424
|
1,949
|
EBITDA
1 |
-297.5
|
7.022
|
-329.7
|
-35.41
|
-10.84
|
1,003
|
1,527
|
EBIT
1 |
-390
|
-132.8
|
-486.4
|
-191.9
|
-166.2
|
-104.5
|
1,180
|
Operating Margin
|
-55.36%
|
-18.38%
|
-117.64%
|
-34.08%
|
-33.8%
|
-7.34%
|
60.54%
|
Earnings before Tax (EBT)
1 |
-578.7
|
-183.3
|
-470.9
|
-269.3
|
-194.8
|
320.5
|
1,200
|
Net income
1 |
-578.7
|
-183.3
|
-470.9
|
-269.3
|
-194.8
|
241.7
|
960
|
Net margin
|
-82.14%
|
-25.37%
|
-113.91%
|
-47.83%
|
-39.61%
|
16.97%
|
49.26%
|
EPS
2 |
-2.300
|
-0.7300
|
-1.870
|
-1.070
|
-0.7700
|
0.9570
|
3.800
|
Free Cash Flow
1 |
-776.9
|
-254.3
|
-219.4
|
-
|
-31.54
|
-397
|
723
|
FCF margin
|
-110.27%
|
-35.2%
|
-53.08%
|
-
|
-6.41%
|
-27.88%
|
37.1%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
47.35%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
75.31%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/03/20
|
26/03/21
|
31/03/22
|
10/03/23
|
20/03/24
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
75.86
|
40.67
|
99.28
|
96.58
|
326.5
|
71.77
|
104.2
|
157.6
|
158.2
|
178.9
|
132.5
|
187.5
|
196.5
|
EBITDA
1 |
-203.2
|
-63.11
|
-16.43
|
-
|
-
|
-32.02
|
-26.47
|
35.41
|
12.23
|
1.706
|
76
|
113
|
111
|
EBIT
1 |
-242.2
|
-102.2
|
-55.56
|
-59.41
|
25.33
|
-71.14
|
-65.3
|
-3.289
|
-26.5
|
-37.05
|
-38.5
|
-17
|
-13.5
|
Operating Margin
|
-319.34%
|
-251.31%
|
-55.96%
|
-61.52%
|
7.76%
|
-99.13%
|
-62.64%
|
-2.09%
|
-16.75%
|
-20.7%
|
-29.06%
|
-9.07%
|
-6.87%
|
Earnings before Tax (EBT)
1 |
-298.7
|
-119.8
|
-75.77
|
-
|
-
|
-80.8
|
-47.84
|
-5.878
|
-60.29
|
-16.04
|
-39
|
-17.5
|
-13
|
Net income
1 |
-298.7
|
-119.8
|
-75.77
|
-35.98
|
-37.78
|
-80.8
|
-47.84
|
-5.878
|
-60.29
|
-16.04
|
-37
|
-17.5
|
-15
|
Net margin
|
-393.77%
|
-294.47%
|
-76.31%
|
-37.25%
|
-11.57%
|
-112.59%
|
-45.89%
|
-3.73%
|
-38.1%
|
-8.96%
|
-27.92%
|
-9.33%
|
-7.63%
|
EPS
2 |
-1.190
|
-0.4700
|
-0.3000
|
-0.1400
|
-0.1500
|
-0.3200
|
-0.1900
|
-0.0200
|
-0.2400
|
-0.0600
|
-0.1400
|
-0.0600
|
-0.0500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/03/22
|
13/05/22
|
15/08/22
|
11/11/22
|
10/03/23
|
12/05/23
|
11/08/23
|
14/11/23
|
20/03/24
|
14/05/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
462
|
471
|
-
|
-
|
Net Cash position
1 |
1,274
|
36.1
|
15.6
|
-
|
-
|
824
|
1,787
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-13.04
x
|
-43.43
x
|
-
|
-
|
Free Cash Flow
1 |
-777
|
-254
|
-219
|
-
|
-31.5
|
-397
|
723
|
ROE (net income / shareholders' equity)
|
-15.1%
|
-5.24%
|
-14.8%
|
-9.52%
|
-7.38%
|
21.6%
|
31.8%
|
ROA (Net income/ Total Assets)
|
-12.2%
|
-3.69%
|
-9.6%
|
-
|
-4.87%
|
-0.5%
|
21.8%
|
Assets
1 |
4,761
|
4,964
|
4,904
|
-
|
3,997
|
-48,335
|
4,404
|
Book Value Per Share
2 |
14.20
|
15.20
|
11.70
|
10.70
|
10.10
|
10.10
|
13.90
|
Cash Flow per Share
2 |
-2.600
|
-0.8000
|
-0.8400
|
-2.400
|
-0.1000
|
-0.1400
|
4.210
|
Capex
1 |
122
|
53.6
|
8.17
|
-
|
5.94
|
100
|
100
|
Capex / Sales
|
17.25%
|
7.42%
|
1.98%
|
-
|
1.21%
|
7.02%
|
5.13%
|
Announcement Date
|
26/03/20
|
26/03/21
|
31/03/22
|
10/03/23
|
20/03/24
|
-
|
-
|
Last Close Price
89.4
TWD Average target price
137
TWD Spread / Average Target +53.27% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.02% | 749M | | +16.64% | 122B | | +19.89% | 115B | | +21.22% | 26.64B | | -23.57% | 19.91B | | -17.47% | 16.32B | | -45.95% | 15.52B | | -18.52% | 15.49B | | +62.46% | 14.83B | | +2.46% | 13.67B |
Bio Therapeutic Drugs
|